Tubastatin A HCl

製品コードS2627

Tubastatin A HCl化学構造

分子量(MW):371.86

Tubastatin A HCl is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).

サイズ 価格(税別)  
JPY 26560.00
JPY 19920.00
JPY 44820.00
JPY 78020.00
JPY 144420.00

カスタマーフィードバック(3)

  • Control and MEC17 KD macrophages (RAW264.7) were treated with TBSA or DMSO for 12 hours followed by LPS treatment for indicated time. p38 phosphorylation were determined by immuno-blotting.

    Nat Commun 2014 5, 3479. Tubastatin A HCl purchased from Selleck.

    Tubastatin A gefitinib-induced apoptosis in NSCLC cells via activation of AKT. H358 cells were treated as described in Figure 4. Representative immunoblots of cleaved caspase-3, AKT and ERK1/2 and of their respective phosphorylated forms are shown. Actin was used as a protein-level control.

    Int J Cancer 2014 134(11):2560-71. Tubastatin A HCl purchased from Selleck.

  • GH cells were treated with 0.5 μM TSA or the DMSO solvent as indicated. Subsequently, Chromatin immunoprecipitation (ChIP) was performed with antibodies to NF-YB or a pre-immune control antibody. The DNA corresponding to the indicated promoters was quantified by real-time PCR and displayed in relation to the amount of input DNA. Bars indicate the standard error from three independent experiments.

    Oncotarget, 2016, 7(23):33484-97. Tubastatin A HCl purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Tubastatin A HCl is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).
ターゲット
HDAC6 [1]
(Cell-free assay)
HDAC8 [1]
(Cell-free assay)
15 nM 854 nM
体外試験

Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity. In homocysteic acid (HCA) induced neurodegeneration assays, Tubastatin A displays dose-dependent protection against HCA-induced neuronal cell death starting at 5 μM with near complete protection at 10 μM. [1] At 100 ng/mL Tubastatin A increases Foxp3+ T-regulatory cells (Tregs) suppression of T cell proliferation in vitro. [2] Tubastatin A treatment in C2C12 cells would lead to myotube formation impairment when alpha-tubulin is hyperacetylated early in the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyeperacetylated in myotubes. [3] A recent study indicates that Tubastatin A treatment increases cell elasticity as revealed by atomic force microscopy (AFM) tests without exerting drastic changes to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
neuron cultures MmixT4lv[XOnIHHzd4F6 MVSyMlUh|ryP NWWzS3o5TE2VTx?= NH3IOHlqdmS3Y3XzJO6yNXS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=> NV\mUlRLOjB4MUS5N|Y>
neuron cultures NFS1V2NHfW6ldHnvckBie3OjeR?= NGLVNFR,OTBizszN MUfEUXNQ MnTQdJJwfGWldIOgZYdicW6|dDDncJV1[XSqaX;u[UBl\XCuZYTpc44ucW6mdXPl[EBwgGmmYYTpeoUhe3S{ZYPz NFrMcIszODZzNEmzOi=>
134/04 MX;GeY5kfGmxbjDhd5NigQ>? MXW3MlUhyrWP NYi1doNDcW2yYXnyd{BugW:2dXLlJIZwem2jdHnvci=> MmLFNlIyPzR6M{m=
C2C12 NV;aPJJrTnWwY4Tpc44h[XO|YYm= NIr1UZM4NjViwsXN M1TGOolueGGrcoOgcZlwfHWkZTDmc5Ju[XSrb36= M4nRe|IzOTd2OEO5
HaCaT keratinocytes NVzQXWZ4TnWwY4Tpc44h[XO|YYm= MoC3NVAh|ryP MWHicI9kc3NiYYLz[Y5qfGViZoLvcUBqdmS3Y3nu[{BPemZ{IIDyc5RmcW5idILhcpNt[XSrb36= NVPRTJJZOjJ|Nke2PFk>
JURL-MK1 Mom3SpVv[3Srb36gZZN{[Xl? NVXVbIs2OTBizszN MY\lcohidmOnczDj[YxtKGGmaHXzbZZqfHlidH:g[oljem:wZXP0bY4> MmrRNlMxOjJ3OEO=
CML-T1 NGnQZldHfW6ldHnvckBie3OjeR?= NWLISmRwOTBizszN M1XHbYVvcGGwY3XzJINmdGxiYXTo[ZNqfmm2eTD0c{BncWK{b37lZ5Rqdg>? NX76enBDOjNyMkK1PFM>
K562 MX3GeY5kfGmxbjDhd5NigQ>? MYixNEDPxE1? Mm\G[Y5p[W6lZYOgZ4VtdCCjZHjld4l3cXS7IITvJIZq[nKxbnXjeIlv M1Llb|I{ODJ{NUiz
HL-60 NVyzcoM5TnWwY4Tpc44h[XO|YYm= M{m5WlExKM7:TR?= NV[5enZx\W6qYX7j[ZMh[2WubDDh[Ihme2m4aYT5JJRwKG[rYoLvcoVkfGmw MkK4NlMxOjJ3OEO=
KMCH NICzZXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MljHglExKM7:TR?= MXrk[YNz\WG|ZYOgdJJwdGmoZYLheIlwdiCjbnSgZY5kcG:{YXflMYlv\GWyZX7k[Y51KGe{b4f0bC=> Mnv3NlM{PzB|Mke=
THP-1 NWezbVV[TnWwY4Tpc44h[XO|YYm= MUT+NVAh|ryP M{TjR4lvcGmkaYTzJHRPTi4QsTDhcoQhUUxvNjDz[YNz\XSrb36= NIT6WXAzOzV2MU[zOC=>
RAW 264.7 M3e1R2Z2dmO2aX;uJIF{e2G7 NUDBUG5ThjFyIN88US=> MU\heJRmdnWjdHXzJG5QKHC{b3T1Z5Rqd25? NUHq[o5KOjN3NEG2N|Q>
HT3 Mn;CSpVv[3Srb36gZZN{[Xl? NUPkbHRrhjVizszN M4[0SmROW09? NUPRNYhbcW6mdXPld{B1cGViZHnm[oVz\W62aXHsJO6yNXS3YoXsbY4h[WOndInsZZRqd25? M1zNeFI{Pjl6NE[4
SiHa NYTJXpdiTnWwY4Tpc44h[XO|YYm= M17Sep42KM7:TR?= M1\2cWROW09? MlrtbY5lfWOnczD0bIUh\GmoZnXy[Y51cWGuIN8xMZR2[nWuaX6gZYNmfHmuYYTpc44> MYGyN|Y6QDR4OB?=
CaSki MWDGeY5kfGmxbjDhd5NigQ>? MkiyglUh|ryP MYfEUXNQ MYrpcoR2[2W|IITo[UBlcW[oZYLlcpRq[WxizsGteJVjfWyrbjDhZ4V1gWyjdHnvci=> MUOyN|Y6QDR4OB?=
SiHa Moi4SpVv[3Srb36gZZN{[Xl? M{Pje542KM7:TR?= NHzLdGNFVVOR M{nXeYlvcGmkaYTzJHRp[XC|aXfhdodqdi1ib4KgSWdHNWmwZIXj[YQhW0:FRTDhZ5RqfmG2aX;u MonYNlM3QTh2Nki=
CaSki MmDjSpVv[3Srb36gZZN{[Xl? Ml\vglUh|ryP NEjMVIVFVVOR MYPpcohq[mm2czDUbIFxe2mpYYLnbY4uKG:{IFXHSk1qdmS3Y3XkJHNQS0ViYXP0bZZifGmxbh?= MoLlNlM3QTh2Nki=
MCF-7 M2jCe2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{jNZVMxKM7:TR?= MXnEUXNQ NEfNOWtKSzVyPUG1JO69VQ>? NFGxdo4zOzd7OE[4NC=>
MCF-7 MWHGeY5kfGmxbjDhd5NigQ>? M1jCeVMxKM7:TR?= NWrGdo5STE2VTx?= MYnpcoNz\WG|ZYOgeIhmKG2rY4LveJVjfWynIHHj[ZR6dGG2aX;uJIxmfmWuLh?= MWmyN|c6QDZ6MB?=
MCF-7 M1H1RWZ2dmO2aX;uJIF{e2G7 NHrIV4o{OCEQvF2= NUfxephVTE2VTx?= MWTzeIFjcWyrenXzJI1q[3KxdIXieYxmeyCjZ3HpcpN1KGOxbHStbY5lfWOnZDDk[ZBwdHmvZYLpfoF1cW:w MkP4NlM4QTh4OEC=
MCF-7 MXzGeY5kfGmxbjDhd5NigQ>? MnPYNVUh|ryP MVPEUXNQ MUHzeIFjcWyrenXzJI1q[3KxdIXieYxmeyCjZ3HpcpN1KG6xY3;kZZpwdGVvaX7keYNm\CCmaYPhd5NmdWKueR?= NXLqd2ZUOjN5OUi2PFA>
MCF-7 MkDGSpVv[3Srb36gZZN{[Xl? M3:3eVMxKM7:TR?= MV\EUXNQ Ml;tZYx1\XKnczD0bIUh[XO|ZX3icJkh\HmwYX3pZ5Mhd2ZiaX70[ZJxcGG|ZTDtbYNzd3S3YoXs[ZM> NH7BdXozOzd7OE[4NC=>
MCF-7 MWDGeY5kfGmxbjDhd5NigQ>? NFu1PIg{OCEQvF2= M3HycmROW09? NH3NcJhqdmO{ZXHz[ZMhfGinIHLpcoRqdmdib3[gTGRCSzZid3n0bEBqdnSncoDoZZNmKG2rY4LveJVjfWyncx?= NHzPWnQzOzd7OE[4NC=>
PC12 MkHDSpVv[3Srb36gZZN{[Xl? MYj+N{DPxE1? NEPyTmhFVVOR NG\pOJF2eC2{ZXf1cIF1\XNiYX70bU1wgGmmYYTpeoUh\2WwZTDlfJBz\XO|aX;uJJJmdGG2ZXSgeI8hfHKjboPjdolxfGmxbjDmZYN1d3JiWFLQNZM> MkP6NlQ6ODl4OE[=
PC12 NGrod4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2rEUJ4{KM7:TR?= M4rLXGROW09? MkPKdoV3\XK|ZTDINm8zNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> M{jORlI1QTB7Nki2
HEK293T M{nqTWZ2dmO2aX;uJIF{e2G7 MWL+N{DPxE1? M{XofmROW09? MmDTeZAuemWpdXzheIVlKFiEUEHzJJBzd3SnaX6gcIV3\Wx? M1n5bFI1QTB7Nki2
HEK293T M3T2U2Z2dmO2aX;uJIF{e2G7 M13KTJ4{KM7:TR?= NYfHUmVuTE2VTx?= NHvWW3Fl\WyjeYOgXGJROXNicILveIVqdiCmZXfyZYRifGmxbjD2bYEh[WOndInsZZRqd25vbXXkbYF1\WRicILveIVie2:vYXyg[IVoemGmYYTpc44> MnPmNlQ6ODl4OE[=
Huh7 NYfI[GZuTnWwY4Tpc44h[XO|YYm= MlLuglUh|ryP MYXEUXNQ M{HMOJN2eHC{ZYPz[ZMheHKxbHnm[ZJifGmxbjDv[kBp\XCjdHn0bZMhSyC4aYL1d{Bz\XCuaXPvckB4cXSqIFXDOVAhRSByLkOg{txO M2DEWFI2OTB6M{K2
SKMEL21 NX;lXXk3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnLHglUxOCCwTR?= NGDqSYxFVVOR NX;GfVdUcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NITVUmYzPTl3N{ixNi=>
SKMEL103 M4TNOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFjMWFd,PTByIH7N NFuyV3NFVVOR MkDxbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NIfXRZEzPTl3N{ixNi=>
SKMEL28 NFHs[lRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIq4N5l,PTByIH7N M3:5U2ROW09? MkDtbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NFLhe3UzPTl3N{ixNi=>
WM164 M3vyXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2jPfZ42ODBibl2= NVrj[WJnTE2VTx?= NHzqOZFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NV20R497OjV7NUe4NVI>
WM1361a MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH\pTnN,PTByIH7N NUjuR2YxTE2VTx?= NEntR|NqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MmnONlU6PTd6MUK=
WM1366 NV2xUlQ2T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3\y[542ODBibl2= MoDHSG1UVw>? NF3aZY9qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NFrGOlIzPTl3N{ixNi=>
WM793 MkfNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MXL+OVAxKG6P MmjJSG1UVw>? Mor6bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u MUGyOVk2PzhzMh?=
WM35 NX6zT5N[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mn7SglUxOCCwTR?= NHO5SGpFVVOR Mle0bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NYTUR21MOjV7NUe4NVI>
WM983a M4Xmd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkWxglUxOCCwTR?= MlT6SG1UVw>? MVfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MXSyOVk2PzhzMh?=
WM793 MlrESpVv[3Srb36gZZN{[Xl? MU\+OkDPxE1? NWjxN|JrTE2VTx?= M1PNSIlv\HWlZTDHNUBienKnc4S= MlXRNlU6PTd6MUK=
WM164 MXvGeY5kfGmxbjDhd5NigQ>? MmH0glYh|ryP MYTEUXNQ MmrubY5lfWOnIFexJIFzemW|dB?= MljoNlU6PTd6MUK=
WM983a NYHJZWE6TnWwY4Tpc44h[XO|YYm= M3HWd543KM7:TR?= M1XzOGROW09? NIrqemZqdmS3Y3WgS|Eh[XK{ZYP0 Mm\JNlU6PTd6MUK=
WM164 NULnbIo4TnWwY4Tpc44h[XO|YYm= MYT+N{DPxE1? NULIepFDTE2VTx?= MYjheYdu\W62czDlfJBz\XO|aX;uJI9nKE2KQzDjcIF{eyCLIHHu[EBu\Wyjbn;tZUBie3OxY3nheIVlKGGwdHnn[Y5{ NFvoNmIzPTl3N{ixNi=>
WM983a MkXBSpVv[3Srb36gZZN{[Xl? MUT+N{DPxE1? MUDEUXNQ NUDKNoFm[XWpbXXueJMh\XiycnXzd4lwdiCxZjDNTGMh[2yjc4OgTUBidmRibXXsZY5wdWFiYYPzc4Nq[XSnZDDhcpRq\2Wwcx?= M1L4e|I2QTV5OEGy
IPC298 NX3lWYJCTnWwY4Tpc44h[XO|YYm= M4XFSp4{KM7:TR?= MkHlSG1UVw>? NFHBcm9ifWevZX70d{BmgHC{ZYPzbY9vKG:oIF3IR{BkdGG|czDJJIFv\CCvZXzhco9u[SCjc4PvZ4lifGWmIHHueIlo\W6| Mn2xNlU6PTd6MUK=
SKMEL30 M1foSmZ2dmO2aX;uJIF{e2G7 M2rBc54{KM7:TR?= NYX3UIpKTE2VTx?= NXHvZmFr[XWpbXXueJMh\XiycnXzd4lwdiCxZjDNTGMh[2yjc4OgTUBidmRibXXsZY5wdWFiYYPzc4Nq[XSnZDDhcpRq\2Wwcx?= M2LwVFI2QTV5OEGy
TCa83 MkTZSpVv[3Srb36gZZN{[Xl? MXvpcoR2[2W|IGDUSW4h\XiycnXzd4lwdiCjbnSgcYVu[nKjbnWgeJJidnOub3PheIlwdg>? MYCyOlI4QTNyMx?=
293T NHO3c3BHfW6ldHnvckBie3OjeR?= MU\+NkDPxGdxbXy= Ml3JbY5lfWOnczDQWGVPKGW6cILld5Nqd25iYX7kJI1mdWK{YX7lJJRz[W6|bH;jZZRqd25? NIPDR2QzPjJ5OUOwNy=>
SACC-83 M4HHOWZ2dmO2aX;uJIF{e2G7 NUWwWGtIhjJizsznM41t MXLpcoR2[2W|IGDUSW4h\XiycnXzd4lwdiCjbnSgcYVu[nKjbnWgeJJidnOub3PheIlwdg>? MY[yOlI4QTNyMx?=
293T M4\oXWZ2dmO2aX;uJIF{e2G7 M1jwfJ4zKM7:Zz;tcC=> MkHybY5lfWOnczDQWGVPKGGlZYT5cIF1cW:wIHH0JGsyPjN? NUW3fJNmOjZ{N{mzNFM>
U-87 MG M{HSUmZ2dmO2aX;uJIF{e2G7 MnjqglIh|rypL33s MV;pcohq[mm2czD0bIUhdWmpcnH0bY9vKGGwZDDpcpZie2mxbh?= M1y5O|I3Ojd7M{Cz
U-87 MG NEHmO4lHfW6ldHnvckBie3OjeR?= NYDpVVlVhjFyIN88US=> NHW2[IdqdmirYnn0d{BCU1RicHjvd5Bpd3K7bHH0bY9v MnjlNlYzPzl|MEO=
U-87 MG NYX6RYF[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4LveJ4yOCEQvF2= MX;pcohq[mm2czDj[YxtKGe{b4f0bC=> MWSyOlI4QTNyMx?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Daily treatment of Tubastatin A at 0.5mg/kg inhibits HDAC6 to promote Tregs suppressive activity in mouse models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully major histocompatibility complex (MHC)-incompatible cardiac allograft rejection. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Enzyme Inhibition Assays:

Enzyme inhibition assays are performed by the Reaction Biology Corporation, Malvern, PA, using the Reaction Biology HDAC Spectrum platform. (www.reactionbiology.com) The HDAC1, 2, 4, 5, 6, 7, 8, 9, 10, and 11 assays use isolated recombinant human protein; HDAC3/NcoR2 complex is used for the HDAC3 assay. Substrate for HDAC1, 2, 3, 6, 10, and 11 assays is a fluorogenic peptide from p53 residues 379-382 (RHKKAc); substrate for HDAC8 is fluorogenic diacyl peptide based on residues 379-382 of p53 (RHKAcKAc). Acetyl-Lys (trifluoroacetyl)-AMC substrate is used for HDAC4, 5, 7, and 9 assays. Tubastatin A is dissolved in DMSO and tested in 10-dose IC50 mode with 3-fold serial dilution starting at 30 μM. Control Compound Trichostatin A (TSA) is tested in a 10-dose IC50 with 3-fold serial dilution starting at 5 μM. IC50 values are extracted by curve-fitting the dose/response slopes.
細胞試験: [1]
+ 展開
  • 細胞株: Primary cortical neuron of fetal Sprague-Dawley rats (embryonic day 17)
  • 濃度: 0-10 μM
  • 反応時間: 24 hours
  • 実験の流れ: Primary cortical neuron cultures are obtained from the cerebral cortex of fetal Sprague-Dawley rats (embryonic day 17) as described previously. All experiments are initiated 24 hours after plating. Under these conditions, the cells are not susceptible to glutamate-mediated excitotoxicity. For cytotoxicity studies, cells are rinsed with warm PBS and then placed in minimum essential medium (Invitrogen) containing 5.5 g/L glucose, 10% fetal calf serum, 2 mM L-glutamine, and 100 μM cystine. Oxidative stress is induced by the addition of the glutamate analogue homocysteate (HCA; 5 mM) to the media. HCA is diluted from 100-fold concentrated solutions that are adjusted to pH 7.5. In combination with HCA, neurons are treated with Tubastatin A at the indicated concentrations. Viability is assessed after 24 hours by MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Na?ve CD45RBhi CD4+ CD25- cells (1 × 106) from WT or HDAC6-/- mice Are injected i.p. into B6/Rag1-/-mice.
  • 製剤: Tubastatin A is dissolved in dimethyl sulfoxide (DMSO).
  • 投薬量: 0.5 mg/kg
  • 投与方法: Tubastatin A is injected i.p. daily.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 74 mg/mL (198.99 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
1% DMSO+30% polyethylene glycol+1% Tween 80
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 371.86
化学式

C20H21N3O2.HCl

CAS No. 1310693-92-5
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Tubastatin A HClを買う | Tubastatin A HCl ic50 | Tubastatin A HCl供給者 | Tubastatin A HClを購入する | Tubastatin A HCl費用 | Tubastatin A HCl生産者 | オーダーTubastatin A HCl | Tubastatin A HCl化学構造 | Tubastatin A HCl分子量 | Tubastatin A HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID